There is one clinical trial.
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19. The study may last up to 9 weeks and include daily visits up to day 28, and follow-up visits by phone.
Description: Number of days on which a participant breathes without assistance
Measure: Number of Ventilator Free Days Time: Day 1 to Day 28Description: The scale is an assessment of clinical status. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities
Measure: Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment Time: Day 1 to Day 28Description: Survival without Respiratory Failure
Measure: Percentage of Participants who are Alive and Respiratory Failure Free Time: Day 1 to Day 28Description: Mortality
Measure: Mortality Time: Day 1 to Day 28Description: Days of Hospitalization
Measure: Length of Hospitalization Time: Day 1 to Day 28Description: Number of Participants with any Serious Adverse Event (SAE)
Measure: Number of Participants with any Serious Adverse Event (SAE) Time: Day 1 to Day 28Description: Number of Participants with any Treatment Emergent Adverse Event (TEAE)
Measure: Number of Participants with any Treatment Emergent Adverse Event (TEAE) Time: Day 1 to Day 28